ArticleMolecular cancer therapeutics2019
Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 117 citations in OpenAlex.
- Targeting PKGIα CysScience advances · 2026Article
- Health Benefits and Molecular Mechanisms of Urolithin A: From a Gut Microbiota-Derived Metabolite to Translational Applications.Food science & nutrition · 2026Review
- An AI-derived peptide PCa2 suppresses pancreatic cancer growth via modulation of the ErbB/PI3K/AKT/mTOR/MYC signaling axis.Cell communication and signaling : CCS · 2026Article
- Gut microbiota drives cancer evolution and therapy resistance.Molecular cancer · 2026Review
- Functional Food-Derived Urolithins: Molecular Mechanisms, Health Effects, and Interactomics with Proteins and Extracellular Vesicles.Molecules (Basel, Switzerland) · 2026Review
- Microbiome as a prediction of immunotherapy response in lung cancer.Frontiers in immunology · 2026Review
- mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics.Signal transduction and targeted therapy · 2025Review
- Multifaceted effects of the microbiome in pancreatic cancer: from association to modulation.Nature reviews. Gastroenterology & hepatology · 2025Review
- Gut microbiota and radiation-induced injury: mechanistic insights and microbial therapies.Gut microbes · 2025Review
- Design, synthesis and biological evaluation of novel urolithin derivatives targeting liver cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Microbial Metabolite, Macro Impact: Urolithin A in the Nexus of Insulin Resistance and Colorectal Tumorigenesis.Nutrients · 2025Review
- Neuroprotective Attributes of Gut-derived Urolithins in Parkinson's Disease.Molecular neurobiology · 2025Review
- The Emerging Role of Mitochondrial Dysfunction in Thyroid Cancer: Mediating Tumor Progression, Drug Resistance, and Reshaping of the Immune Microenvironment.Biomolecules · 2025Review
- Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1.Scientific reports · 2025Article
- Efficacy of urolithin B-Loaded mesoporous silica nanoparticles modified with graphene quantum Dots against MCF-7 breast Cancer cells.Scientific reports · 2025Article
- Urolithin A Protects Ovarian Reserve Via Inhibiting PI3K/Akt Signaling and Preventing Chemotherapy-Induced Follicle Apoptosis.Biology · 2025Article
- Urolithin A Attenuates Periodontitis in Mice via Dual Anti-Inflammatory and Osteoclastogenesis Inhibition: A Natural Metabolite-Based Therapeutic Strategy.Molecules (Basel, Switzerland) · 2025Article
- Urolithins' interaction with hepatocyte growth factor receptor: a mechanistic basis for anticancer activity in gastric adenocarcinoma cells.Discover oncology · 2025Article
- Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages.Journal of advanced research · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Tulasigeri M Totiger *Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Supriya Srinivasan *Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Venkatakrishna R JalaDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
Purushottam LamichhaneDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Austin R DoschDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Alexander A GaidarskiDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Chandrashekhar JoshiDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Shobith RangappaAdichunchanagiri Institute for Molecular Medicine, AIMS, Karnataka, India.
Jason CastellanosDepartment of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee.
Praveen Kumar VemulaInstitute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, Karnataka, India.
Xi ChenDepartment of Public Health, University of Miami Miller School of Medicine, Miami, Florida.
Deukwoo KwonDepartment of Public Health, University of Miami Miller School of Medicine, Miami, Florida.
Nilesh KashikarDepartment of Pathology, University of Colorado, Denver, Colorado.
Michael VanSaunDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Nipun B MerchantDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Nagaraj S NagathihalliDepartment of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida. nnagathihalli@med.miami.edu.
Sylvester Comprehensive Cancer Center · USUniversity of Miami · USAims Community College · USInstitute for Stem Cell Biology and Regenerative Medicine · INUniversity of Colorado Denver · USUniversity of Louisville · USVanderbilt University · US
Funding
Stat3 Signaling in Pancreas CancerR01CA161976 · NCI · VANDERBILT UNIVERSITY · PI MERCHANT, NIPUN B. · 2012 to 2022
$3.4MResearch Training Program in Surgical OncologyT32CA211034 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MERCHANT, NIPUN B. · 2016 to 2025
$2.7MPQ-10: Microbial metabolite, Urolithin A is a potent immunomodulator and chemosensitizing adjuvant in treating colon cancer.R21CA216090 · NCI · UNIVERSITY OF LOUISVILLE · PI JALA, VENKATAKRISHNA RAO · 2017 to 2018
$368kTargeting cytokine mediated CREB activation in pancreatic cancerR21CA209536 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI NAGATHIHALLI, NAGARAJ S. · 2016 to 2017
$367kNCI NIH HHS R01 CA161976NCI NIH HHS R21 CA209536NCI NIH HHS R21 CA216090NCI NIH HHS T32 CA211034
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against
Indexed as
AnimalsAntineoplastic Agents, PhytogenicCarcinoma, Pancreatic DuctalCell Line, TumorCell ProliferationCell SurvivalCoumarinsHumansLythraceaeMicePancreatic NeoplasmsPhosphatidylinositol 3-KinasesPhosphorylationProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine Kinases3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneAntineoplastic Agents, PhytogenicCoumarinsMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.